Cancer
Kaplan Fox Seeks to Recover Losses for Investors Who Purchased the Publicly Traded Securities of Amgen Inc.
Published in Drug Law Weekly, May 29th, 2007
Today, Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) filed a class action suit in the United States District Court for the Central District of California on behalf of all persons who purchased the publicly traded securities of Amgen Inc. ("Amgen" or the "Company") from May 4, 2005 through May 10, 2007 (the "Class Period") against Amgen and certain of its officers and directors for violations of the Securities Exchange Act of 1934.
The Complaint alleges, inter alia, that during the Class Period, defendants improperly marketed Amgen's anti-anemia drugs Aranesp and Epogen to doctors for off-label uses. As a result, Amgen sold several hundred million dollars worth of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-05-29)
More Articles from Drug Law Weekly
- Alzheimer Disease
Interim report for the first quarter of 2007 - Autism
University of Missouri Study on Link Between Autism and Mercury a Discredit to Sound Science, Says SafeMinds - Biosyntrx Inc.
Biosyntrx Inc. Becomes Voting Member of Council for Responsible Nutrition - Cancer
Advancement of Internal Cancer Drug Discovery Program - Clinical Trial Research
Scientists at Monash University report research in clinical trial research - Drug Abuse
Ritalin Abuse Poses Risk During College Exam Week - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
